Nations Financial Group Inc. IA ADV Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

Nations Financial Group Inc. IA ADV cut its stake in Johnson & Johnson (NYSE:JNJ) by 5.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,249 shares of the company’s stock after selling 2,000 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in Johnson & Johnson were worth $4,714,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Scott & Selber Inc. lifted its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Scott & Selber Inc. now owns 15,660 shares of the company’s stock worth $2,289,000 after buying an additional 91 shares during the last quarter. Rather & Kittrell Inc. lifted its holdings in Johnson & Johnson by 4.4% during the 2nd quarter. Rather & Kittrell Inc. now owns 3,224 shares of the company’s stock worth $471,000 after buying an additional 137 shares during the last quarter. Innealta Capital LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $27,000. F M Investments LLC lifted its holdings in Johnson & Johnson by 2,851.4% during the 2nd quarter. F M Investments LLC now owns 91,849 shares of the company’s stock worth $13,421,000 after buying an additional 88,737 shares during the last quarter. Finally, Smith Chas P & Associates PA Cpas lifted its holdings in Johnson & Johnson by 8.4% during the 2nd quarter. Smith Chas P & Associates PA Cpas now owns 262,225 shares of the company’s stock worth $38,327,000 after buying an additional 20,311 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $165.86 on Friday. The business’s 50 day simple moving average is $155.34 and its 200-day simple moving average is $153.45. The firm has a market capitalization of $399.17 billion, a price-to-earnings ratio of 10.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $165.98.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.80 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 2.99%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. TD Securities decreased their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. The Goldman Sachs Group cut their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Monday, August 5th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.